Drug-resistant cytomegalovirus in transplant recipients: a French cohort study
Sébastien Hantz(Université de Limoges), Alexandra Ducancelle, Marie‐Edith Lafon, Vincent Foulongne, Michel Segondy, Y Lebranchu(Centre Hospitalier Universitaire de Tours), Bruno Pozzetto(Université Claude Bernard Lyon 1), Pierre Merville(Centre National de la Recherche Scientifique), Pascal Turlure(Centre Hospitalier Universitaire de Limoges), Patrice Morand, Christine Archimbaud, Jean‐Baptiste Bour, Florence Morfin, Patrice André, F. Garnier-Geoffroy(Centre Hospitalier Universitaire de Limoges), L. Rostaing(Centre Hospitalier Universitaire de Toulouse), Joël Grosjean, Sébastien Cotin(Université de Limoges), Catherine Mengelle, Jean‐Michel Mansuy(Université Fédérale de Toulouse Midi-Pyrénées), Raymond Césaire(Centre Hospitalier Universitaire de Liège), Christine Morel-Baccard, F. Saint Marcoux(Centre Hospitalier Universitaire de Limoges), I. Garrigue, Sophie Alain(Inserm), H. Peigue‐Lafeuille, Vinca Domenach, G. Herbein, S. Pillet, C. Henquell, Marie Essig, S. Gaudio-Castelain, F. Majioullah, Anne Signori-Schmück, Jean-Philippe Rérolle(Université de Limoges), Marie‐Christine Mazeron(Université Paris Cité), A. Beby‐Defaux, G. Agius, Marie-Paule Milon, Geneviève Billaud, A. Coaquette, Pierre Pothier, Raphaële Germi(Centre National de la Recherche Scientifique)
Cited by 163
Related Papers
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|994
Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy
|The Lancet Infectious Diseases|2017|822
COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
|Nephrology Dialysis Transplantation|2020|411
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
|Haematologica|2018|349
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
|Clinical Infectious Diseases|2021|299